secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acutus Medical, Inc. (—)
CIK:        0001522860
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950103-23-016107
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 2.06, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acutus Medical to exit mapping/ablation, cut 65% workforce, CEO to step down, focus on Medtronic left-heart access
--------------------------------------------------------------------------------

- Workforce reduction of ~160 employees (~65% of total) expected to be completed by Q1 2024.
- Estimated $21M-$32M pre-tax restructuring charges; majority non-cash impairment in Q4 2023, cash charges in Q1 2024.
- President & CEO David Roman to depart Jan 7, 2024; CFO Takeo Mukai appointed CEO effective Jan 8, 2024.
- Q3 2023 revenue $5.2M (+44% YoY); GAAP net loss $13.2M ($0.45 loss per share).
- Company will wind down mapping/ablation products and focus solely on left-heart access distribution for Medtronic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1522860/000095010323016107/0000950103-23-016107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1522860/000095010323016107/dp202619_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-23-016107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer